Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications

Oxidative Medicine and Cellular Longevity

Volumn 2017, Issue , 2017, Pages

  Liu, Zewen ^a,b   Zhou, Tingyang ^a,c   Ziegler, Alexander C ^d   Dimitrion, Peter ^d   Zuo, Li ^a,c  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b WUHAN UNIVERSITY   (China)

^c OHIO STATE UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANTS; DISEASE CONTROL; OXYGEN; POLYUNSATURATED FATTY ACIDS;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT DEFENSE; CLINICAL APPLICATION; COGNITIVE FUNCTIONS; HUNTINGTON'S DISEASE; MOLECULAR PATHOGENESIS; NEURODEGENERATIVE DISORDERS; REACTIVE OXYGEN SPECIES;

NEURODEGENERATIVE DISEASES;

REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CONTROLLED CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE SEVERITY; HUMAN; HUNTINGTON CHOREA; MITOCHONDRION; MOLECULAR PATHOLOGY; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW; SPINOCEREBELLAR DEGENERATION; ANIMAL; GENETICS; PATHOLOGY;

DISEASES; OXYGEN; SPECIES IDENTIFICATION;

ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 85026545246     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2017/2525967     Document Type: Review

References (141)

1. Alzheimer's Association, "2016 Alzheimer's disease facts and figures, " Alzheimer's & Dementia, vol. 12, pp. 459-509, 2016.
2. H. R. Silvade, N. L. Khan, and N. W. Wood, "The genetics of Parkinson's disease, " Current Opinion in Genetics & Development, vol. 10, pp. 292-298, 2000.
3. D. S. Albers and M. F. Beal, "Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease, " Journal of Neural Transmission Supplementum, vol. 59, pp. 133-154, 2000.
4. A. Matilla-Duenas, T. Ashizawa, A. Brice et al., "Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias, " Cerebellum, vol. 13, pp. 269-302, 2014.
5. M. Hamer and Y. Chida, "Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence, " Psychological Medicine, vol. 39, pp. 3-11, 2009.
6. M. C. Rijkde, L. J. Launer, K. Berger et al., "Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts, " Neurology, vol. 54, pp. S21-SS3, 2000.
7. L. M. Bekris, I. F. Mata, and C. P. Zabetian, "The genetics of Parkinson disease, " Journal of Geriatric Psychiatry and Neurology, vol. 23, pp. 228-242, 2010.
8. M. J. Farrer, "Genetics of Parkinson disease: paradigm shifts and future prospects, " Nature Reviews Genetics, vol. 7, pp. 306-318, 2006.
9. Alzheimer's Association, "2011 Alzheimer's disease facts and figures, " Alzheimer's & Dementia, vol. 7, pp. 208-244, 2011.
10. L. Zuo, M. S. Koozechian, and L. L. Chen, "Characterization of reactive nitrogen species in allergic asthma, " Annals of Allergy Asthma & Immunology, vol. 112, pp. 18-22, 2014.
11. L. Zuo, T. Zhou, B. K. Pannell, A. C. Ziegler, and T. M. Best, "Biological and physiological role of reactive oxygen species-the good, the bad and the ugly, " Acta Physiologica, vol. 214, pp. 329-348, 2015.
12. F. He and L. Zuo, "Redox roles of reactive oxygen species in cardiovascular diseases, " International Journal of Molecular Sciences, vol. 16, pp. 27770-27780, 2015.
13. L. Zuo, A. Shiah, W. J. Roberts, M. T. Chien, P. D. Wagner, and M. C. Hogan, "Low Po2 conditions induce reactive oxygen species formation during contractions in single skeletal muscle fibers, " American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 304, pp. R1009-R1016, 2013.
14. V. Dias, E. Junn, and M. M. Mouradian, "The role of oxidative stress in Parkinson's disease, " Journal of Parkinson's Disease, vol. 3, pp. 461-491, 2013.
15. J. St-Pierre, S. Drori, M. Uldry et al., "Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators, " Cell, vol. 127, pp. 397-408, 2006.
16. K. Hensley, M. Mhatre, S. Mou et al., "On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis, " Antioxidants & Redox Signaling, vol. 8, pp. 2075-2087, 2006.
17. A. C. Rego and C. R. Oliveira, "Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases, " Neurochemical Research, vol. 28, pp. 1563-1574, 2003.
18. R. L. Mosley, E. J. Benner, I. Kadiu et al., "Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's disease, " Clinical Neuroscience Research, vol. 6, pp. 261-281, 2006.
19. T. Wyss-Coray and L. Mucke, "Inflammation in neurodegenerative disease-a double-edged sword, " Neuron, vol. 35, pp. 419-432, 2002.
20. M. T. Lin and M. F. Beal, "Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases, " Nature, vol. 443, pp. 787-795, 2006.
21. V. Campuzano, L. Montermini, Y. Lutz et al., "Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes, " Human Molecular Genetics, vol. 6, pp. 1771-1780, 1997.
22. D. C. Wallace, "Mitochondrial diseases in man and mouse, " Science, vol. 283, pp. 1482-1488, 1999.
23. C. A. Ross and S. J. Tabrizi, "Huntington's disease: from molecular pathogenesis to clinical treatment, " Lancet Neurology, vol. 10, pp. 83-98, 2011.
24. M. Sano, C. Ernesto, R. G. Thomas et al., "A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease, " The New England Journal of Medicine, vol. 336, pp. 1216-1222, 1997.
25. L. I. Golbe, T. M. Farrell, and P. H. Davis, "Case-control study of early life dietary factors in Parkinson's disease, " Archives of Neurology, vol. 45, pp. 1350-1353, 1988.
26. E. J. Pappert, C. C. Tangney, C. G. Goetz et al., "Alphatocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels, " Neurology, vol. 47, pp. 1037-1042, 1996.
27. R. Skouta, "Neuroprotective effect of antioxidant compounds, " Neural Regeneration Research, vol. 11, pp. 566-567, 2016.
28. R. Skouta, S. J. Dixon, J. Wang et al., "Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models, " Journal of the American Chemical Society, vol. 136, pp. 4551-4556, 2014.
29. Y. Gilgun-Sherki, E. Melamed, and D. Offen, "Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier, " Neuropharmacology, vol. 40, pp. 959-975, 2001.
30. G. H. Kim, J. E. Kim, S. J. Rhie, and S. Yoon, "The role of oxidative stress in neurodegenerative diseases, " Experimental Neurobiology, vol. 24, pp. 325-340, 2015.
31. L. Zuo, B. T. Hemmelgarn, C. C. Chuang, and T. M. Best, "The role of oxidative stress-induced epigenetic alterations in amyloid-beta production in Alzheimer's disease, " Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 604658, 13 pages, 2015.
32. H. W. Querfurth and F. M. LaFerla, "Alzheimer's disease, " The New England Journal of Medicine, vol. 362, pp. 329-344, 2010.
33. D. A. Butterfield, "The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment, " Free Radical Biology & Medicine, vol. 74, pp. 157-174, 2014.
34. E. Ferreiro, C. R. Oliveira, and C. M. Pereira, "The release of calcium from the endoplasmic reticulum induced by amyloid-beta and prion peptides activates the mitochondrial apoptotic pathway, " Neurobiology of Disease, vol. 30, pp. 331-342, 2008.
35. D. J. Bonda, X. Wang, G. Perry et al., "Oxidative stress in Alzheimer disease: a possibility for prevention, " Neuropharmacology, vol. 59, pp. 290-294, 2010.
36. W. J. Huang, X. Zhang, and W. W. Chen, "Role of oxidative stress in Alzheimer's disease, " Biomedical Reports, vol. 4, pp. 519-522, 2016.
37. T. Nakamura and S. A. Lipton, "Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases, " Cell Death and Differentiation, vol. 18, pp. 1478-1486, 2011.
38. T. Nakamura and S. A. Lipton, "Preventing Ca2+?mediated nitrosative stress in neurodegenerative diseases: possible pharmacological strategies, " Cell Calcium, vol. 47, pp. 190-197, 2010.
39. D. A. Patten, M. Germain, M. A. Kelly, and R. S. Slack, "Reactive oxygen species: stuck in the middle of neurodegeneration, " Journal of Alzheimer's Disease, vol. 20, Supplement 2, pp. S357-S367, 2010.
40. P. B. Shelat, M. Chalimoniuk, J. H. Wang et al., "Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons, " Journal of Neurochemistry, vol. 106, pp. 45-55, 2008.
41. E. Giraldo, A. Lloret, T. Fuchsberger, and J. Vina, "Abeta and tau toxicities in Alzheimer's are linked via oxidative stressinduced p38 activation: protective role of vitamin E, " Redox Biology, vol. 2, pp. 873-877, 2014.
42. N. Bulat and C. Widmann, "Caspase substrates and neurodegenerative diseases, " Brain Research Bulletin, vol. 80, pp. 251-267, 2009.
43. P. Agostinho, J. P. Lopes, Z. Velez, and C. R. Oliveira, "Overactivation of calcineurin induced by amyloid-beta and prion proteins, " Neurochemistry International, vol. 52, pp. 1226-1233, 2008.
44. A. Awasthi, Y. Matsunaga, and T. Yamada, "Amyloid-beta causes apoptosis of neuronal cells via caspase cascade, which can be prevented by amyloid-beta-derived short peptides, " Experimental Neurology, vol. 196, pp. 282-289, 2005.
45. A. Hamilton and C. Holscher, "The effect of ageing on neurogenesis and oxidative stress in the APPswe/PS1deltaE9 mouse model of Alzheimer's disease, " Brain Research, vol. 1449, pp. 83-93, 2012.
46. M. L. Block, "NADPH oxidase as a therapeutic target in Alzheimer's disease, " BMC Neuroscience, vol. 9, Supplement 2, p. S8, 2008.
47. G. S. Aseervatham, T. Sivasudha, R. Jeyadevi, and A. D. Arul, "Environmental factors and unhealthy lifestyle influence oxidative stress in humans-an overview, " Environmental Science and Pollution Research International, vol. 20, pp. 4356-4369, 2013.
48. M. A. Smith, X. Zhu, M. Tabaton et al., "Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment, " Journal of Alzheimer's Disease, vol. 19, pp. 363-372, 2010.
49. E. R. Stadtman, "Protein oxidation in aging and age-related diseases, " Annals of the new York Academy of Sciences, vol. 928, pp. 22-38, 2001.
50. C. Holmes, C. Cunningham, E. Zotova et al., "Systemic inflammation and disease progression in Alzheimer disease, " Neurology, vol. 73, pp. 768-774, 2009.
51. M. Johnstone, A. J. Gearing, and K. M. Miller, "A central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytokines and reactive oxygen species are produced, " Journal of Neuroimmunology, vol. 93, pp. 182-193, 1999.
52. T. J. Seabrook, L. Y. Jiang, M. Maier, and C. A. Lemere, "Minocycline affects microglia activation, a beta deposition, and behavior in APP-tg mice, " Glia, vol. 53, pp. 776-782, 2006.
53. W. Y. Wang, M. S. Tan, J. T. Yu, and L. Tan, "Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease, " Annals of Translational Medicine, vol. 3, p. 136, 2015.
54. M. Nizzari, S. Thellung, A. Corsaro et al., "Neurodegeneration in Alzheimer disease: role of amyloid precursor protein and presenilin 1 intracellular signaling, " Journal of Toxicology, vol. 2012, Article ID 187297, 13 pages, 2012.
55. D. A. Butterfield and D. Boyd-Kimball, "The critical role of methionine 35 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity, " Biochimica et Biophysica Acta, vol. 1703, pp. 149-156, 2005.
56. C. C. Curtain, F. Ali, I. Volitakis et al., "Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits, " The Journal of Biological Chemistry, vol. 276, pp. 20466-20473, 2001.
57. M. W. Dysken, P. D. Guarino, J. E. Vertrees et al., "Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data, " Alzheimer's & Dementia, vol. 10, pp. 36-44, 2014.
58. D. J. Selkoe, "Alzheimer's disease: genes, proteins, and therapy, " Physiological Reviews, vol. 81, pp. 741-766, 2001.
59. M. Dumont and M. F. Beal, "Neuroprotective strategies involving ROS in Alzheimer disease, " Free Radical Biology and Medicine, vol. 51, pp. 1014-1026, 2011.
60. K. Kanninen, T. M. Malm, H. K. Jyrkkanen et al., "Nuclear factor erythroid 2-related factor 2 protects against beta amyloid, " Molecular and Cellular Neurosciences, vol. 39, pp. 302-313, 2008.
61. S. Jeon, J. Hur, H. J. Jeong, B. S. Koo, and S. C. Pak, "SuHeXiang wan essential oil alleviates amyloid beta induced memory impairment through inhibition of tau protein phosphorylation in mice, " The American Journal of Chinese Medicine, vol. 39, pp. 917-932, 2011.
62. F. Yang, G. P. Lim, A. N. Begum et al., "Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo, " The Journal of Biological Chemistry, vol. 280, pp. 5892-5901, 2005.
63. L. Lannfelt, K. Blennow, H. Zetterberg et al., "And group PEs. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial, " Lancet Neurology, vol. 7, pp. 779-786, 2008.
64. J. Graff and L. H. Tsai, "The potential of HDAC inhibitors as cognitive enhancers, " Annual Review of Pharmacology and Toxicology, vol. 53, pp. 311-330, 2013.
65. J. Labbadia and R. I. Morimoto, "Huntington's disease: underlying molecular mechanisms and emerging concepts, " Trends in Biochemical Sciences, vol. 38, pp. 378-385, 2013.
66. J. Gil-Mohapel, P. S. Brocardo, and B. R. Christie, "The role of oxidative stress in Huntington's disease: are antioxidants good therapeutic candidates?, " Current Drug Targets, vol. 15, pp. 454-468, 2014.
67. F. Mochel and R. G. Haller, "Energy deficit in Huntington disease: why it matters, " The Journal of Clinical Investigation, vol. 121, pp. 493-499, 2011.
68. J. G. Hodgson, N. Agopyan, C. A. Gutekunst et al., "A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration, " Neuron, vol. 23, pp. 181-192, 1999.
69. S. W. Davies, M. Turmaine, B. A. Cozens et al., "Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation, " Cell, vol. 90, pp. 537-548, 1997.
70. L. Cui, H. Jeong, F. Borovecki, C. N. Parkhurst, N. Tanese, and D. Krainc, "Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration, " Cell, vol. 127, pp. 59-69, 2006.
71. P. Weydt, V. V. Pineda, A. E. Torrence et al., "Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration, " Cell Metabolism, vol. 4, pp. 349-362, 2006.
72. A. Kumar and R. R. Ratan, "Oxidative stress and Huntington's disease: the good, the bad, and the ugly, " Journal of Huntington's Disease, vol. 5, pp. 217-237, 2016.
73. A. Covarrubias-Pinto, P. Moll, M. Solis-Maldonado et al., "Beyond the redox imbalance: oxidative stress contributes to an impaired GLUT3 modulation in Huntington's disease, " Free Radical Biology and Medicine, vol. 89, pp. 1085-1096, 2015.
74. L. P. Reagan, A. M. Magarinos, D. K. Yee et al., "Oxidative stress and HNE conjugation of GLUT3 are increased in the hippocampus of diabetic rats subjected to stress, " Brain Research, vol. 862, pp. 292-300, 2000.
75. M. Bonora, M. R. Wieckowsk, C. Chinopoulos et al., "Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition, " Oncogene, vol. 34, p. 1608, 2015.
76. A. V. Panov, C. A. Gutekunst, B. R. Leavitt et al., "Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines, " Nature Neuroscience, vol. 5, pp. 731-736, 2002.
77. E. Bossy-Wetzel, A. Petrilli, and A. B. Knott, "Mutant huntingtin and mitochondrial dysfunction, " Trends in Neurosciences, vol. 31, pp. 609-616, 2008.
78. G. Liot, J. Valette, J. Pepin, J. Flament, and E. Brouillet, "Energy defects in Huntington's disease: why "in vivo" evidence matters, " Biochemical and Biophysical Research Communications, vol. 483, no. 4, pp. 1084-1095, 2017.
79. C. Zuccato, M. Valenza, and E. Cattaneo, "Molecular mechanisms and potential therapeutical targets in Huntington's disease, " Physiological Reviews, vol. 90, pp. 905-981, 2010.
80. J. P. Bolanos, M. A. Moro, I. Lizasoain, and A. Almeida, "Mitochondria and reactive oxygen and nitrogen species in neurological disorders and stroke: therapeutic implications, " Advanced Drug Delivery Reviews, vol. 61, pp. 1299-1315, 2009.
81. I. Tunez, F. Sanchez-Lopez, E. Aguera, R. Fernandez-Bolanos, F. M. Sanchez, and I. Tasset-Cuevas, "Important role of oxidative stress biomarkers in Huntington's disease, " Journal of Medicinal Chemistry, vol. 54, pp. 5602-5606, 2011.
82. N. Klepac, M. Relja, R. Klepac, S. Hecimovic, T. Babic, and V. Trkulja, "Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects: a crosssectional study, " Journal of Neurology, vol. 254, pp. 1676-1683, 2007.
83. I. Ciancarelli, D. AmicisDe, C. MassimoDi et al., "Influence of intensive multifunctional neurorehabilitation on neuronal oxidative damage in patients with Huntington's disease, " Functional Neurology, vol. 30, pp. 47-52, 2015.
84. M. A. Sorolla, G. Reverter-Branchat, J. Tamarit, I. Ferrer, J. Q. Ros, and E. Cabiscol, "Proteomic and oxidative stress analysis in human brain samples of Huntington disease, " Free Radical Biology and Medicine, vol. 45, pp. 667-678, 2008.
85. T. Y. C. Pang, N. C. Stam, J. Nithianantharajah, M. L. Howard, and A. J. Hannan, "Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice, " Neuroscience, vol. 141, pp. 569-584, 2006.
86. R. M. Arida, F. A. Scorza, and E. A. Cavalheiro, "Role of physical exercise as complementary treatment for epilepsy and other brain disorders, " Current Pharmaceutical Design, vol. 19, pp. 6720-6725, 2013.
87. S. E. Browne, R. J. Ferrante, and M. F. Beal, "Oxidative stress in Huntington's disease, " Brain Pathology, vol. 9, pp. 147-163, 1999.
88. M. C. Polidori, P. Mecocci, S. E. Browne, U. Senin, and M. F. Beal, "Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex, " Neuroscience Letters, vol. 272, pp. 53-56, 1999.
89. E. Miller, A. Morel, L. Saso, and J. Saluk, "Isoprostanes and neuroprostanes as biomarkers of oxidative stress in neurodegenerative diseases, " Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 572491, 10 pages, 2014.
90. R. S. Sohal and R. Weindruch, "Oxidative stress, caloric restriction, and aging, " Science, vol. 273, pp. 59-63, 1996.
91. A. L. McCormack, M. Thiruchelvam, A. B. Manning-Bog et al., "Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat, " Neurobiology of Disease, vol. 10, pp. 119-127, 2002.
92. L. X. Qin, J. Q. Tan, H. N. Zhang et al., "BAG5 interacts with DJ-1 and inhibits the neuroprotective effects of DJ-1 to combat mitochondrial oxidative damage, " Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 5094934, 10 pages, 2017.
93. K. Apel and H. Hirt, "Reactive oxygen species: metabolism, oxidative stress, and signal transduction, " Annual Review of Plant Biology, vol. 55, pp. 373-399, 2004.
94. S. J. Chinta and J. K. Andersen, "Redox imbalance in Parkinson's disease, " Biochimica et Biophysica Acta, vol. 1780, pp. 1362-1367, 2008.
95. J. Meiser, D. Weindl, and K. Hiller, "Complexity of dopamine metabolism, " Cell Communication and Signaling: CCS, vol. 11, p. 34, 2013.
96. S. Gangemi, E. Gofita, C. Costa et al., "Occupational and environmental exposure to pesticides and cytokine pathways in chronic diseases (review), " International Journal of Molecular Medicine, vol. 38, pp. 1012-1020, 2016.
97. R. Perfeito, T. Cunha-Oliveira, and A. C. Rego, "Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse, " Free Radical Biology and Medicine, vol. 53, pp. 1791-1806, 2012.
98. L. Zuo and M. S. Motherwell, "The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease, " Gene, vol. 532, pp. 18-23, 2013.
99. V. Adam-Vizi, "Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources, " Antioxidants & Redox Signaling, vol. 7, pp. 1140-1149, 2005.
100. E. M. Valente, P. M. Abou-Sleiman, V. Caputo et al., "Hereditary early-onset Parkinson's disease caused by mutations in PINK1, " Science, vol. 304, pp. 1158-1160, 2004.
101. H. Jiang, Y. Ren, J. Zhao, and J. Feng, "Parkin protects human dopaminergic neuroblastoma cells against dopamineinduced apoptosis, " Human Molecular Genetics, vol. 13, pp. 1745-1754, 2004.
102. G. Ganguly, S. Chakrabarti, U. Chatterjee, and L. Saso, "Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease, " Drug Design, Development and Therapy, vol. 11, pp. 797-810, 2017.
103. N. A. Mazo, V. Echeverria, R. Cabezas et al., "Medicinal plants as protective strategies against Parkinson's disease, " Current Pharmaceutical Design, vol. 23, 2017.
104. P. I. Moreira, X. Zhu, X. Wang et al., "Mitochondria: a therapeutic target in neurodegeneration, " Biochimica et Biophysica Acta, vol. 1802, pp. 212-220, 2010.
105. S. A. Zaitone, D. M. Abo-Elmatty, and A. A. Shaalan, "Acetyl-L-carnitine and alpha-lipoic acid affect rotenoneinduced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy, " Pharmacology, Biochemistry, and Behavior, vol. 100, pp. 347-360, 2012.
106. I. Shoulson, "DATATOP: a decade of neuroprotective inquiry. Parkinson study group. Deprenyl and tocopherol Antioxidative therapy of parkinsonism, " Annals of Neurology, vol. 44, pp. S160-S166, 1998.
107. S. Fahn, "A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease, " Annals of Neurology, vol. 32, Supplement, pp. S128-S132, 1992.
108. M. Etminan, S. S. Gill, and A. Samii, "Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis, " Lancet Neurology, vol. 4, pp. 362-365, 2005.
109. C. W. Shults, D. Oakes, K. Kieburtz et al., "Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline, " Archives of Neurology, vol. 59, pp. 1541-1550, 2002.
110. M. H. Yan, X. Wang, and X. Zhu, "Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease, " Free Radical Biology and Medicine, vol. 62, pp. 90-101, 2013.
111. M. C. Kiernan, S. Vucic, B. C. Cheah et al., "Amyotrophic lateral sclerosis, " Lancet, vol. 377, pp. 942-955, 2011.
112. J. P. Taylor, R. H. Brown Jr., and D. W. Cleveland, "Decoding ALS: from genes to mechanism, " Nature, vol. 539, pp. 197-206, 2016.
113. C. Ingre, P. M. Roos, F. Piehl, F. Kamel, and F. Fang, "Risk factors for amyotrophic lateral sclerosis, " Clinical Epidemiology, vol. 7, pp. 181-193, 2015.
114. J. Gamez, M. Corbera-Bellalta, G. Nogales et al., "Mutational analysis of the cu/Zn superoxide dismutase gene in a Catalan ALS population: should all sporadic ALS cases also be screened for SOD1?, " Journal of the Neurological Sciences, vol. 247, pp. 21-28, 2006.
115. R. A. Saccon, R. K. Bunton-Stasyshyn, E. M. Fisher, and P. Fratta, "Is SOD1 loss of function involved in amyotrophic lateral sclerosis?, " Brain, vol. 136, pp. 2342-2358, 2013.
116. E. L. Bastow, A. R. Peswani, D. S. J. Tarrant et al., "New links between SOD1 and metabolic dysfunction from a yeast model of amyotrophic lateral sclerosis, " Journal of Cell Science, vol. 129, pp. 4118-4129, 2016.
117. Q. Li, N. Y. Spencer, N. J. Pantazis, and J. F. Engelhardt, "Alsin and SOD1(G93A) proteins regulate endosomal reactive oxygen species production by glial cells and proinflammatory pathways responsible for neurotoxicity, " The Journal of Biological Chemistry, vol. 286, pp. 40151-40162, 2011.
118. E. D'Amico, P. Factor-Litvak, R. M. Santella, and H. Mitsumoto, "Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis, " Free Radical Biology and Medicine, vol. 65, pp. 509-527, 2013.
119. J. Lee, S. J. Hyeon, H. Im, H. Ryu, Y. Kim, and H. Ryu, "Astrocytes and microglia as non-cell autonomous players in the pathogenesis of ALS, " Experimental Neurobiology, vol. 25, pp. 233-240, 2016.
120. P. Mondola, S. Damiano, A. Sasso, and M. Santillo, "The cu, Zn superoxide dismutase: not only a dismutase enzyme, " Frontiers in Physiology, vol. 7, p. 594, 2016.
121. P. Mondola, M. Santillo, R. Seru et al., "Cu, Zn superoxide dismutase increases intracellular calcium levels via a phospholipase C-protein kinase C pathway in SK-N-BE neuroblastoma cells, " Biochemical and Biophysical Research Communications, vol. 324, pp. 887-892, 2004.
122. P. Mondola, G. Ruggiero, R. Seru et al., "The Cu, Zn superoxide dismutase in neuroblastoma SK-N-BE cells is exported by a microvesicles dependent pathway, " Brain Research Molecular Brain Research, vol. 110, pp. 45-51, 2003.
123. P. Mondola, T. Annella, R. Seru et al., "Secretion and increase of intracellular CuZn superoxide dismutase content in human neuroblastoma SK-N-BE cells subjected to oxidative stress, " Brain Research Bulletin, vol. 45, pp. 517-520, 1998.
124. S. Damiano, T. Petrozziello, V. Ucci, S. Amente, M. Santillo, and P. Mondola, "Cu-Zn superoxide dismutase activates muscarinic acetylcholine M1 receptor pathway in neuroblastoma cells, " Molecular and Cellular Neurosciences, vol. 52, pp. 31-37, 2013.
125. Q. J. Yu and Y. Yang, "Function of SOD1, SOD2, and PI3K/ AKT signaling pathways in the protection of propofol on spinal cord ischemic reperfusion injury in a rabbit model, " Life Sciences, vol. 148, pp. 86-92, 2016.
126. D. Davila and I. Torres-Aleman, "Neuronal death by oxidative stress involves activation of FOXO3 through a two-arm pathway that activates stress kinases and attenuates insulinlike growth factor I signaling, " Molecular Biology of the Cell, vol. 19, pp. 2014-2025, 2008.
127. M. Nagai, D. B. Re, T. Nagata et al., "Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons, " Nature Neuroscience, vol. 10, pp. 615-622, 2007.
128. A. Gustin, M. Kirchmeyer, E. Koncina et al., "NLRP3 Inflammasome is expressed and functional in mouse brain microglia but not in astrocytes, " PloS One, vol. 10, article e0130624, 2015.
129. E. Foran, A. Bogush, M. Goffredo et al., "Motor neuron impairment mediated by a sumoylated fragment of the glial glutamate transporter EAAT2, " Glia, vol. 59, pp. 1719-1731, 2011.
130. K. Li, T. J. Hala, S. Seetharam, D. J. Poulsen, M. C. Wright, and A. C. Lepore, "GLT1 overexpression in SOD1(G93A) mouse cervical spinal cord does not preserve diaphragm function or extend disease, " Neurobiology of Disease, vol. 78, pp. 12-23, 2015.
131. M. Rossi, S. Perez-Lloret, L. Doldan et al., "Autosomal dominant cerebellar ataxias: a systematic review of clinical features, " European Journal of Neurology, vol. 21, pp. 607-615, 2014.
132. M. U. Manto, "The wide spectrum of spinocerebellar ataxias (SCAs), " Cerebellum, vol. 4, pp. 2-6, 2005.
133. Y. M. Sun, C. Lu, and Z. Y. Wu, "Spinocerebellar ataxia: relationship between phenotype and genotype-a review, " Clinical Genetics, vol. 90, pp. 305-314, 2016.
134. H. Y. Zoghbi and H. T. Orr, "Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1, " The Journal of Biological Chemistry, vol. 284, pp. 7425-7429, 2009.
135. D. M. Stucki, C. Ruegsegger, S. Steiner et al., "Mitochondrial impairments contribute to spinocerebellar ataxia type 1 progression and can be ameliorated by the mitochondriatargeted antioxidant MitoQ, " Free Radical Biology and Medicine, vol. 97, pp. 427-440, 2016.
136. A. H. Hakonen, S. Goffart, S. Marjavaara et al., "Infantileonset spinocerebellar ataxia and mitochondrial recessive ataxia syndrome are associated with neuronal complex I defect and mtDNA depletion, " Human Molecular Genetics, vol. 17, pp. 3822-3835, 2008.
137. A. Federico, E. Cardaioli, P. PozzoDa, P. Formichi, G. N. Gallus, and E. Radi, "Mitochondria, oxidative stress and neurodegeneration, " Journal of the Neurological Sciences, vol. 322, pp. 254-262, 2012.
138. R. Lodi, P. E. Hart, B. Rajagopalan et al., "Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia, " Annals of Neurology, vol. 49, pp. 590-596, 2001.
139. M. P. Murphy, "Antioxidants as therapies: can we improve on nature?" Free Radical Biology and Medicine, vol. 66, pp. 20-23, 2014.
140. B. Uttara, A. V. Singh, P. Zamboni, and R. T. Mahajan, "Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options, " Current Neuropharmacology, vol. 7, pp. 65-74, 2009.
141. Z. X. Yao, K. Drieu, and V. Papadopoulos, "The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands, " Brain Research, vol. 889, pp. 181-190, 2001.